Iterum Therapeutics plc 8-K

What Happened Iterum Therapeutics plc announced that at its extraordinary general meeting on February 18, 2026 shareholders voted down four key proposals that would have enabled new financing and a reverse share split. The proposals rejected were: (1) increase authorized share capital from $1,800,000 to $2,300,000 by creating 50,000,000 ordinary shares; (2) updated directors’ authority to allot and issue shares, warrants, convertible instruments and options; (3) opt-out of pre-emption rights (allowing cash issuances without first offering to existing shareholders); and (4) a reverse share split consolidating between 10-to-1 and 15-to-1 and reducing nominal value to $0.01. The company filed the 8-K on February 18, 2026; the report was signed by CEO Corey N. Fishman.

Key Details

• Vote results (For / Against / Abstain):
  • Authorized share capital increase: 12,841,845 / 17,872,597 / 107,794
  • Directors’ allotment authority: 13,050,107 / 17,595,857 / 176,272
  • Pre-emption rights opt-out: 12,774,691 / 17,867,413 / 180,132
  • Reverse share split: 13,904,954 / 16,689,179 / 195,638
• No broker non-votes arose for these matters (each was treated as "routine" under NYSE rules).
• Following the vote, the company stated these results restrict its ability to raise additional capital and said its operations, financial condition and ability to continue as a going concern are likely to be materially and adversely affected.
• Iterum is continuing to evaluate corporate, strategic and financial alternatives, including potential licensing, sale/divestiture of assets, a wind-down, or possible bankruptcy/liquidation, but noted limited time and resources and no assurance any transaction will occur.

Why It Matters For investors, the vote removes board-authorized tools that would have made new equity financings and a share consolidation easier. That increases near-term financing risk: the company itself warns the outcome may materially harm operations and raises the possibility of a wind-down or bankruptcy, in which shareholders are unlikely to receive meaningful recovery. The filing signals elevated risk to the company’s ability to continue as a going concern and underscores that any strategic transaction is uncertain and time‑constrained.